BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9830391)

  • 1. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
    Rogers R; Prpic R
    Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 3. The short life and rapid death of a novel antihypertensive and antianginal agent.
    Krum H; McNeil JJ
    Med J Aust; 1998 Oct; 169(8):408-9. PubMed ID: 9830386
    [No Abstract]   [Full Text] [Related]  

  • 4. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mibefradil--a new calcium-channel blocker.
    Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
    [No Abstract]   [Full Text] [Related]  

  • 6. The withdrawal of mibefradil (Posicor).
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
    Alpert JS
    Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
    [No Abstract]   [Full Text] [Related]  

  • 8. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
    Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound sinus bradycardia due to diltiazem, verapamil, and/or beta-adrenergic blocking drugs.
    Mills TA; Kawji MM; Cataldo VD; Pappas ND; O'Meallie LP; Breaux DM; Glancy DL
    J La State Med Soc; 2004; 156(6):327-31. PubMed ID: 15688675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
    Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
    J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
    [No Abstract]   [Full Text] [Related]  

  • 11. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
    Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment: mibefradil, a new class of calcium-channel antagonists.
    Otterman S
    Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
    [No Abstract]   [Full Text] [Related]  

  • 14. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What lessons can be learnt from withdrawal of mibefradil from the market?
    Po AL; Zhang WY
    Lancet; 1998 Jun; 351(9119):1829-30. PubMed ID: 9652662
    [No Abstract]   [Full Text] [Related]  

  • 16. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 17. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 18. Withdrawal of Posicor from market.
    SoRelle R
    Circulation; 1998 Sep; 98(9):831-2. PubMed ID: 9738634
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current therapy of coronary heart disease. Conservative measures].
    Stephan S
    Internist (Berl); 1998 Sep; 39(9):1001-2. PubMed ID: 9788131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.